y88888

y88888 Commerce Bancshares senior vice president sells $53,364 in stock

Mikel Arteta gets exactly what he wanted as Arsenal smash Sporting to end rotten run

Colorado’s landfills leak climate-warming methane into the air. What’s the state going to do about it?South Korea's President Yoon Suk Yeol will LIFT martial law just hours after stunning the world and declaring emergency

Bears vs. Vikings: 5 bold predictions for Sunday's matchupWhat to know about Northern California's rare tsunami warning

Enrollment and implant procedures completed in NIH funded feasibility study of LGS, a severe and disabling childhood-onset epilepsy MOUNTAIN VIEW, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced completion of enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS® System for the treatment of Lennox-Gastaut Syndrome (LGS), a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury. The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to evaluate whether brain-responsive neurostimulation can also be used to treat LGS. NeuroPace received a $9.3 million National Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative to evaluate its responsive neuromodulation technology in those who suffer from LGS. The IDE study funded by the grant was conducted at six sites and enrolled a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures. The study will evaluate the safety and effectiveness of the RNS System in treating seizures associated with LGS. "We are pleased to announce the advancement of our LGS IDE study and look forward to the data and learnings it provides. The results from this study could support further research of RNS therapy to improve the treatment of people with LGS. We appreciate the dedicated efforts of the investigators, research teams, participants and their families,” said Martha Morrell, MD, Chief Medical Officer of NeuroPace. "After completing the one-year open label period, participants will transition to the long-term follow-up period, which will continue over the next 18 months.” "LGS is a devastating, childhood-onset seizure disorder that leads to lifelong disability. 85% of those with LGS continue to have seizures into adulthood despite aggressive treatment, 98% suffer from intellectual disability, and they are 12 times more likely to die prematurely than others their age," said Tracy Dixon-Salazar, PhD, Executive Director of the LGS Foundation and mother of an adult living with LGS. "LGS families desperately need innovative treatment options to manage their seizures, and we are excited about this new study." Disclaimer: Research reported in this press release was supported by the National Institutes of Health's Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative under award number UH3NS109557. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About the RNS® System The RNS® System, a paradigm-shifting treatment for drug-resistant focal epilepsy, is the only brain-responsive neuromodulation system approved by the FDA. The closed-loop technology delivers personalized, data-driven treatment targeted to the seizure source by continuously monitoring brain activity, recognizing a patient's unique seizure pattern, and responding in real-time with imperceptible stimulation to prevent seizures. By recording ongoing EEG data, the RNS System provides physicians with a unique "window to the brain,” enabling them to remotely monitor their patients, gain insights based on brain activity, and use that information to optimize patient care. Long-term clinical studies demonstrate that the RNS System provides significant reduction in seizure frequency and enduring improvements in quality of life and cognition with no stimulation-related side effects. The RNS System is available at most comprehensive epilepsy centers in the United States and is widely covered by insurance. It is currently approved in the United States as an adjunctive therapy for patients 18 years of age and older with drug-resistant focal epilepsy. See full indication for use and important safety information at www.neuropace.com/safety/ . About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients suffering from drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders. Forward Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims,” "anticipates,” "believes,” "could,” "estimates,” "expects,” "forecasts,” "goal,” "intends,” "may,” "plans,” "possible,” "potential,” "seeks,” "will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace's RNS System and other important factors. These and other risks and uncertainties include those described more fully in the section titled "Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace's public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 12 , 2024, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace's views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace. Investor Contact: Jeremy Feffer Managing Director LifeSci Advisors [email protected]EREV with almost 1,000-mile range: Huawei-Chery launch new Luxeed R7The Half Promise Of Weight-Loss Drugs

Instead, Quinn's Commanders are in the thick of the playoff race even after consecutive losses provided something of a speed bump, while the Cowboys' season has fallen apart . Dallas (3-7) visits Washington (7-4) on Sunday in a franchise role reversal for the NFC East rivals. "For me and for the guys, man, it’s Washington-Dallas Week, let’s get down," Quinn said. “I don’t make one (game) too often bigger than another. I just think they’re all really important, and we absolutely go after it as hard as we can.” Quinn, defensive coordinator Joe Whitt Jr. and a handful of former Dallas players have been part of Washington's turnaround, including pass rusher Dante Fowler, defensive end Dorance Armstrong, center Tyler Biadasz and receiver Noah Brown, who famously caught rookie quarterback Jayden Daniels' Hail Mary toss for the game-winning touchdown last month to beat Chicago . Armstrong has followed the Cowboys' downfall since leaving in free agency, saying simply, “It’s not good.” And that was before a piece of their stadium's roof fell Monday night before their fifth consecutive loss , a 34-10 blowout by Houston . Injuries, including starting QB Dak Prescott's torn hamstring that led to season-ending surgery, have been the backdrop for Dallas' forgettable year. Coach Mike McCarthy, who's approaching the end of his contract and possibly his tenure, said he and his staff are “going to stay the course” and play who's available. That means Cooper Rush again getting the nod in place of Prescott, though McCarthy said a package of plays could open up to get 2021 No. 3 overall draft pick Trey Lance into the game. “Cooper’s been there for a little minute, so he knows the system really good," said Fowler, who leads the Commanders with 8 1/2 sacks. "Trey Lance is really good with his legs, and he’s a dynamic quarterback, as well. You don’t want to go out there half-stepping against those guys because they do play good football, as well.” The Commanders have played far better football than the Cowboys so far this season, so much that the home team is a 10 1/2-point favorite on BetMGM Sportsbook. Washington has never been more than a nine-point favorite against Dallas in any game going back to at least 2003, according to BetMGM. The Cowboys could get a bit of a spark with the anticipated return of receiver Brandin Cooks, who has seen way too much sorrow around him since he last played in Week 4. “Get guys playing at a high level, playing fun, playing free, and having a great time out there,” Cooks said. “That’s what I’m not seeing right now. I think we can go out there and be more joyful in our process.” There's plenty of joy in Washington, with the playoffs still on the line, unlike Dallas. “It’s definitely cool to be in that type of position rather than being on the other side," Fowler said. “Just cool to see what Coach Quinn has just done since he came here with this team and getting a group of guys to come together and play as one.” Daniels gets a reset A rib injury knocked Daniels out of a rout of Carolina on Oct. 20, and while he did not miss a game, the 23-year-old has not been as dangerous or effective since. The No. 2 pick out of LSU and reigning Heisman Trophy winner has completed 59.5% of his passes the past four games after 75.6% before getting injured, and he has had his average rushing yards cut nearly in half from 53.1 to 27.5. Quinn insists Daniels is not injured and pinned the regression on a lack of practice time in recent weeks. Daniels also said he's good to go after some extra rest following a 26-18 loss at Philadelphia on Thursday, Nov. 14. “The mini bye, I think it just helps everything, just to reset your mind and get ready for the second half of the season,” Daniels said. “I was able to reset and refocus, restart.” OL shuffle The offensive line has been a problem all season for the Cowboys. Now it’s a major injury concern. Perennial All-Pro right guard Zack Martin and promising young left guard Tyler Smith sustained ankle injuries on the same drive in the fourth quarter for the Cowboys against the Texans. Neither returned. Rookie left tackle Tyler Guyton re-injured his shoulder trying to run with a fumble after Rush had the ball knocked out of his hand trying to throw. Asim Richards has already filled in for Guyton several times as the first-round draft pick has battled various injuries. T.J. Bass and Brock Hoffman (Virginia Tech) were the replacements at guard. Like Guyton and Smith, all three fill-ins are 25 or younger. It’s possible veteran tackle Chuma Edoga, the projected starter at left tackle before injuring a toe in training camp, could make his season debut. “With Zack, he’s a keystone for our offensive line," McCarthy said. "That will be a big one. But it’s more opportunity for these young players who haven’t played a lot and are getting a lot of work." Running questions McCarthy said the Cowboys “took a step backward, clearly” running the ball against Houston after making progress the previous couple of games. Rico Dowdle, now the clear lead back after ineffectiveness and off-field drama from Ezekiel Elliott, had just 28 yards on 10 carries, and the Cowboys finished with 64 yards. They allowed 141 yards, including 109 and three touchdowns by Joe Mixon, and have the NFL's second-worst rushing defense. Washington's Brian Robinson Jr. has already set a career high with seven TD runs and could be in for a lot of carries. “I look forward to running the ball any time,” Robinson said. “I’m prepared, I’m ready and if it happens like that, I’m ready for it."Brewers love crafting a wide array of beers, but over time, beer drinkers have gravitated dramatically toward two key factors – hoppiness and drinkability.

RICHMOND, Ky. (AP) — Matt Morrissey threw a 67-yard touchdown pass to Marcus Calwise Jr. that ended the scoring midway through the fourth quarter and Eastern Kentucky beat North Alabama 21-15 on Saturday for its fifth straight win. TJ Smith drove North Alabama to the EKU 45-yard line before he threw an interception to Mike Smith Jr. to end the game. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

STATESBORO, Ga. (AP) — Adante' Holiman scored 20 points as Georgia Southern beat West Georgia 64-54 on Saturday. Holiman went 7 of 14 from the field (5 for 9 from 3-point range) for the Eagles (5-2). Dontae Horne added 11 points while going 4 of 8 (3 for 6 from 3-point range) and also had five rebounds and three steals. Tyson Brown and Nakavieon White both had 10 points. Shelton Williams-Dryden led the way for the Wolves (0-6) with 21 points, seven rebounds, four assists and two steals. West Georgia also got 10 points and two steals from Kolten Griffin. Rickey Ballard finished with eight points, 11 rebounds and three steals. The loss was the Wolves' sixth straight. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar . For copyright information, check with the distributor of this item, Data Skrive.

Physicists Found an Entirely New Way of Measuring Time